Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study

BACKGROUND: Obesity is a risk factor for malignancy; however, its prognostic role in patients with metastatic melanoma is controversial. We aim to investigate the prognostic role of body mass index (BMI) in patients with metastatic melanoma receiving mitogen-activated pathway kinase inhibitors (MAPK...

Descripción completa

Detalles Bibliográficos
Autores principales: Rutkowski, Piotr, Indini, Alice, De Luca, Matilde, Merelli, Barbara, Mariuk-Jarema, Anna, Teterycz, Pawel, Rogala, Pawel, Lugowska, Iwona, Cybulska-Stopa, Bożena, Labianca, Alice, Di Guardo, Lorenza, Del Vecchio, Michele, Pigozzo, Jacopo, Randon, Giovanni, Corti, Francesca, Tondini, Carlo Alberto, Rulli, Eliana, Mandala, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674105/
https://www.ncbi.nlm.nih.gov/pubmed/33203662
http://dx.doi.org/10.1136/jitc-2020-001117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674105/
https://www.ncbi.nlm.nih.gov/pubmed/33203662
http://dx.doi.org/10.1136/jitc-2020-001117

Ejemplares similares